When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PRRUF - Immutep Limited: Surging On Positive Head And Neck Data
Immutep Limited
2025-05-08 08:46:59 ET
Summary
Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches.
IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues.
Despite promising phase 2 data, the fate of eftilagimod remains uncertain, with future trials and FDA discussions critical for potential accelerated approval.
The positive TACTI-003 readout strengthens my "Buy" sentiment, though risks remain in this challenging cancer treatment landscape.